

POSTOPERATIVE CHANGES IN PROTEIN C ACTIVITY

T H E S I S

Submitted For Partial Fulfilment Of
Master Degree In Clinical Pathology

By

HANAA MOHAMED EL SAYED AFIFI
Clinical Pathology Department

Supervised By

Prof. Dr. TARIF HAMZA SALLAM
Prof. of Clinical Pathology
Ain Shams University


Prof. Dr. ZEINAB TAWFIK
Assist. Prof. of Clinical Pathology
Ain Shams University

Faculty of Medicine
Ain Shams University

1988

66 0756
H. M







C O N T E N T S

	Page -----
- Introduction	1
- Aim of the Work	3
- Review of Literature	4
- Normal Haemostatis	4
- Thrombosis	19
- Historical discovery of protein C	23
- Protein C, S, Z	26
- Protein C in relation to other vitamin K-dependent factors	28
- Synthesis of Protein C	32
- Structure of protein C	35
- Activation of protein C	39
- Anticoagulant properties of protein C	50
- Variations in protein C level	57
- Therapeutic uses of protein C	78
- Assay of protein C	80
- Protein S	94
- Material and Methods	99

- Results	116
- Discussion	132
- Summary and conclusion	139
- References	143
- Arabic Summary	185

L I S T O F F I G U R E S

		Page -----
Figure I	Pathways to blood coagulation	8
Figure II	A suggested scheme for contact factor activation	9
Figure III	Activators and inhibitors of fibrinolysis	17
Figure IV	Possible interrelationships of some factors contributing to vascular and arterial thrombosis	21
Figure V	Column chromatography of some vitamin K dependent factors in normal plasma pool	29
Figure VI	Comparison of N-terminal amino acid sequences of the vitamin K dependent factors	30
Figure VII	Nucleotide sequence of the cDNA inserts that code for human PC	34
Figure VIII	Amino acid sequence of the light chain of bovine PC	37
Figure IX	Amino acid sequence of the heavy chain of bovine PC	38
Figure X	Partial structure of bovine PC	40

Figure XI	Proposed schematic model for in vivo protein C activation	43
Figure XII	Role of APC in the regulation of haemostasis	50
Figure XIII	Changes in PC in patients before and after major surgery, minor surgery and cancer surgery	69
Figure XIV	Reference curve measuring PC activity percent	108
Figure XV	Bar chart comparing the mean values of PC activity percent	128
Figure XVI	Frequency histogram of preoperative PC activity percent in the studied group of patients	129
Figure XVII	Frequency histogram of the two days postoperative PC activity in the studied group of patients	130
Figure XVIII	Frequency histogram of PC activity percent at the seventh day post-operatively	131

L I S T O F T A B L E S

		Page

Table I	Comparison of PC activity and antigen in type I and type II PC inherited deficiency	75
Table II	Qualities of PC evaluated in its functional assays	84
Table III	Protein C activity in control group of healthy subjects	120
Table IV	Postoperative changes in PC activity in the studies group of patients	121
Table V	Statistical analysis of the results of PC changes postoperatively in the studied group of patients	122
Table VI	One stage prothrombin time pre-operatively in the studied group of patients	123
Table VII	One stage prothrombin time two days postoperatively in the studied group of patients	124
Table VIII	One stage prothrombin time after seven days postoperatively in the studied group of patients	125
Table IX	Partial thromboplastin time values in the studied group of patients	126
Table X	Correlation study between PC, PT and PTT values	127

A B B R E V I A T I O N S

a	Activated.
Ab	Antibody.
Ag	Antigen.
APC	Activated protein C.
APL	Acute promyelocytic leukaemia.
Arg-	Arginine.
Asp-	Aspartic acid.
AT III	Antithrombin III.
Ca ²	Calcium ions.
C ₁	Complement one.
C ₄ b	Complement four fragment (b).
DFP	Diisoprophylflourophosphate.
DIC	Disseminated intravascular coagulopathy.
E. Coli	Escherichia coli.
EDTA	Ethylene diamine tetraacetic acid.
ELIZA	Enzyme linked immunosorbent assay.
et al.	Etalli = and other coworkers.
F	Factor.
Factor I	Fibrinogen.
Factor II	Prothrombin.
Factor III	Tissue factor.

Factor IV	Calcium.
Factor V	Pro-acclerlin.
Factor VII	Pro-convertin.
Factor VIII	Antihaemophilic.
Factor IX	Christmas factor.
Factor X	Stuart-Prower factor.
Factor XI	Plasma thromboplastin antecedent.
Factor XII	Hageman factor.
Factor XIII	Fibrin stabilizing factor.
FDPs	Fibrin degradation products.
Gla-	Gamma carboxyglutamic acid.
Gly-	Glycine.
HMW kininogen	High molecular weight kininogen.
Ile	Isoleucine.
M.Wt.	Molecular weight.
N-terminal	Amino terminal.
PC	Protein C.
PCCs	Protein C concentrates.
Pro-	Proline.
PS	Protein S.
PT	Prothrombin time.
PTT	Partial thromboplastin time.
RVV-X	The protease from Russell's viper venous that activates factor X because it contains VIIa.
Val-	Valine.

S Y M B O L S

α	=	Alpha.
B	=	Beta.
C	=	Degree centigrade.
γ	=	Gamma.
g	=	Gram.
Kg	=	Kilogram.
L	=	Liter.
u	=	Micro.
ug	=	Microgram.
uL	=	Microliter.
mg	=	Milligram.
nm	=	Nanometer.
%	=	Percent.
P	=	Propability.
rpm	=	Revolution per minute.
U	=	Unit.
>	=	More than.
<	=	Less than.

A C K N O W L E D G E M E N T

I wish to express my deep thanks and gratitude to my Professor Dr. Tarif Hamza Sallam, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University for giving me the privilege of working under his supervision, for his encouragement and continuous support.

I also express my deep thanks and gratitude to Dr. Zeinab Tawfik, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University for her great support, encouragement, patience, enthusiasm, criticism, fruitful comments and help without which this work would have never seen light.

I am sincerely indebted to my colleagues, my son, my husband and my parents. To patients and to every one who participated in some way or the other, to let this work come to such a final picture, I owe my thanks and gratitude.

*INTRODUCTION
AND
AIM OF THE
WORK*

I N T R O D U C T I O N

Thromboembolic accidents are known troublesome postoperative complications. It is related to many factors particularly, the type of the operation, age of the patient and many haemostatic factors. The haemostatic dynamic equilibrium is mainly centered upon the delicate balance between the fibrinogenic versus the fibrinolytic processes. Factors affecting the coagulability of blood or affecting the inhibitory systems of blood coagulation are accused as implicated in the pathogenesis of postoperative thromboembolic complications.

Recently, a previously known autoproteithrombin II-A, plasma protein was found to have a regulatory action on the dynamic equilibrium of haemostasis. This protein was first characterized by Stenflo (1976) and named it " Protein C" because it was purified from a protein fraction (Pool C) obtained after gradient elution of a prothrombin complex concentrate on the third peak of DEAE-Sephadex column chromatography.

Stenflo (1976) found that it is a vitamin K-dependent and coumarin-sensitive protein which circulates in the

blood as a zymogen that is converted into its active form by thrombin.

The activated form in vitro is a powerful inhibitor of activated factor V mainly and activated VIII:C and a stimulator of fibrinolysis (Comp and Esmon, 1978). Activated protein is not inhibited by heparin and antithrombin III (Kisiel, 1979) but by a specific inhibitor.

Many recent works are trying to correlate between protein C deficiency and conditions associated with hypercoagulable states.